Skip to main content
SpringerLink
Log in

Is there a place for antipsychotic polypharmacotherapy in schizophrenia?

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999; 12: 179–88

    Article  CAS  Google Scholar 

  2. Brenner HD, Denckner SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 551–61

    Article  PubMed  CAS  Google Scholar 

  3. Satterlee W, Dellva MA, Beasley C, et al. Effectiveness of olanzapine in long-term continuation treatment. Presented at NCDEU: 1997 May; Boca Raton, Florida

    Google Scholar 

  4. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549–57

    Article  PubMed  CAS  Google Scholar 

  5. Zimbroff DL, Kane JM, Tamminga CA, and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782–91

    PubMed  CAS  Google Scholar 

  6. Harrigan EP, Reeves K. The efficacy and safety of low fixed doses of ziprasidone in schizophernia. Presented at NCDEU: 1997 May; Boca Raton, Florida

    Google Scholar 

  7. Kane J, Honigfeld G, Singer J, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1990; 47: 189–90

    Google Scholar 

  8. Beasley CM, Tollefson G, Tran P. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–23

    Article  PubMed  CAS  Google Scholar 

  9. Anon. Clinical psychopharmacology online. Currents 1997; 16: 17-18

  10. Meltzer HY, Lee MA, Ranjan R, et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 1996; 124: 176–87

    Article  PubMed  CAS  Google Scholar 

  11. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1995; 52: 1071–2

    Article  PubMed  CAS  Google Scholar 

  12. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998; 59: 585–8

    Article  PubMed  CAS  Google Scholar 

  13. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996; 57: 395–7

    PubMed  CAS  Google Scholar 

  14. Shiloh R, Zemishlany D, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. Br J Psychiatry 1997; 171: 569–73

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Is there a place for antipsychotic polypharmacotherapy in schizophrenia?. Drugs Ther. Perspect 16, 9–12 (2000). https://doi.org/10.2165/00042310-200016030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200016030-00003

Keywords

Search

Navigation